SynapCell to screen for novel treatments for pharmacoresistant epilepsies
Salt Lake City | January 29th, 2014

The University of Utah awards a subcontract to SynapCell to expand anti-seizure drug screening and testing capabilities in animal models of therapy-resistant epilepsy.

The University of Utah has awarded a one-year subcontract to SynapCell under the Anticonvulsant Screening Program (ASP) contract sponsored by the NIH National Institute of Neurological Disorders and Stroke (NINDS). This subcontract will supplement the existing University of Utah program to test promising anti-seizure drug candidates in a mouse model of therapy-resistant mesial temporal lobe epilepsy (MTLE).